Home » Posts tagged with » Genentech
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107

Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]

Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib

Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and collaboration deal potentially worth up to $1.703 billion for the latter’s cancer drug candidate pralsetinib. Through the deal, Roche gains exclusive rights for the co-development and marketing of the investigational drug for RET-altered cancers across the world […]

Continue reading …
Clover Health launches chronic diseases-focused Clover Therapeutics

California-based healthcare company Clover Health has launched a new research subsidiary, called Clover Therapeutics, which will focus on developing drugs for older adults for the treatment of chronic diseases. Clover Therapeutics has started its journey by signing a research collaboration and license agreement with Roche’s subsidiary Genentech to better understand the genomic factors that increase […]

Continue reading …
Genentech MS drug Ocrevus approved by FDA for multiple sclerosis treatment

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion. The FDA approval has made the Genentech MS drug Ocrevus as the first and only therapy available for the two forms of multiple […]

Continue reading …